We are proud to announce that Diaverum has been accredited with the highest rating of ‘Excellent’ by the Accreditation Centre for Quality in Healthcare (Public Association of Surveyors and Consultants in the field of Healthcare Accreditation) in Kazakhstan.
The accreditation, which applies to our operations across the entire country, is valid for three years and is testament to the standards of excellence we have achieved since entering the Kazakh market in 2015. Diaverum currently provides haemodialysis treatment to more than 2,500 patients across 48 clinics across the country.
Receiving this National Accreditation is a complex, multi-layered process, in which trained external experts and consultants evaluated Diaverum Kazakhstan’s compliance with national regulations and evaluated its measurements against benchmark industry performance standards. The accreditation process occurred in two stages; first, with a comprehensive assessment of all documents, processes, policies and procedures, and following this, onsite visits to our clinics. The implementation of our integrated, patient-centric care delivery model, that delivers benchmark medical outcomes and patient satisfaction levels, both within the company’s global network of clinics as well as industry-wide, has been integral to meeting to the National Accreditation’s exacting standards.
Commenting on the accreditation, Vladimir Gabrielyan, Vice-President Diaverum Eurasia said: “We are very happy and proud that Diaverum Kazakhstan has earned this highest level of recognition. It is a validation of the standards of quality and accountability we have set for ourselves in providing life-enhancing renal care in the country.”
Amantur Ryskulov, Country Managing Director Diaverum Kazakhstan, added: “Preparing for accreditation was a very intensive exercise and relied on a strong collaboration between the clinics, support functions and company’s top management. Our efforts have paid off, since this accreditation is an official and reputable testament to the quality of our renal care provision in the country that will certainly put Diaverum in an even more competitive position to be granted public funding to treat more patients in Kazakhstan”.